Inhibition of IgE production by the imidazoquinoline resiquimod in nonallergic and allergic donors.

The aim of this study was to examine whether the immune modulator resiquimod, which belongs like imiquimod to the imidazoquinolines, is capable of influencing IgE synthesis. Peripheral blood mono-nuclear cells from normal donors and patients with atopic dermatitis and with seasonal allergic rhinitis were analyzed in the presence of resiquimod, anti-CD40+interleukin-4 stimulation for induction of IgE, and anti-CD40+interleukin-4 in the presence of resiquimod, respectively. Our data show that spontaneous IgE production was inhibited in the presence of resiquimod, which was strongest at 10 ng per ml in both groups of allergic patients. Inhibition of IgE production after anti-CD40+interleukin-4 stimulation in the presence of resiquimod (10 ng per ml) was comparable between all the groups. In normal donors median inhibition of IgE synthesis was 93%, in seasonal allergic rhinitis patients 77%, and in patients with atopic dermatitis 72%. In order to rule out antiproliferative effects of resiquimod, which might influence IgE production, we also studied proliferation of peripheral blood mononuclear cells from normal donors, which remained unchanged in the presence of resiquimod at 0.1-10 ng per ml but was inhibited at 100 or 1000 ng per ml. In search of possible mechanisms responsible for the observed inhibition of IgE production, we analyzed the expression and production of molecules that are known to modulate IgE production, namely CD23 and interferon-gamma. CD23 expression on B cells was lower in the presence of resiquimod (10 ng per ml) in anti-CD40+interleukin-4 stimulated cells, whereas interferon-gamma was strongly induced (4-6-fold) by resiquimod (10 ng per ml). Furthermore, by using neutralizing interferon-gamma monoclonal antibodies, we show that inhibition of IgE production occurred in an interferon-gamma-dependent manner. Taken together our results show that resiquimod is a potent modulator of IgE production in vitro in normal but also in allergic donors.

[1]  D. Bernstein,et al.  Immunomodulation as a treatment strategy for genital herpes: review of the evidence. , 2002, International immunopharmacology.

[2]  S. Akira,et al.  Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway , 2002, Nature Immunology.

[3]  D. Bernstein,et al.  Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment. , 2001, The Journal of infectious diseases.

[4]  G. Bishop,et al.  The immune response modifier resiquimod mimics CD40-induced B cell activation. , 2001, Cellular immunology.

[5]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[6]  M. Smith,et al.  Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. , 2000, Cellular immunology.

[7]  T. Haahtela,et al.  Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. , 2000, The Journal of allergy and clinical immunology.

[8]  T. Waldschmidt,et al.  The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. , 2000, Cellular immunology.

[9]  R. Maw,et al.  An audit of patients who have received Imiquimod cream 5% for the treatment of anogenital warts , 2000, International journal of STD & AIDS.

[10]  C. Akdis,et al.  Immunologic mechanisms of specific immunotherapy , 1999, Allergy.

[11]  J. Nyce,et al.  Oligonucleotide therapy of allergic asthma. , 1999, The Journal of allergy and clinical immunology.

[12]  R. Miller,et al.  Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. , 1999, Cellular immunology.

[13]  Williams,et al.  Inhibition of sCD23 and immunoglobulin E release from human B cells by a metalloproteinase inhibitor, GI 129471 , 1998, Immunology.

[14]  D. Cooper,et al.  Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. , 1998, The Journal of infectious diseases.

[15]  S. Tyring,et al.  Imiquimod, a Patient-Applied Immune-Response Modifier for Treatment of External Genital Warts , 1998, Antimicrobial Agents and Chemotherapy.

[16]  S. Spruance,et al.  Treatment of genital warts with an immune-response modifier (imiquimod). , 1998, Journal of the American Academy of Dermatology.

[17]  A. Enk,et al.  Insect venom immunotherapy induces interleukin‐10 production and a Th2‐to‐Th1 shift, and changes surface marker expression in venom‐allergic subjects , 1997, European journal of immunology.

[18]  R. Djukanović,et al.  The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. , 1997, The Journal of clinical investigation.

[19]  M. Gore,et al.  A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. , 1996, British Journal of Cancer.

[20]  J. D. de Vries,et al.  IL-4 induces human B cell maturation and IgE synthesis in SCID-hu mice. Inhibition of ongoing IgE production by in vivo treatment with an IL-4/IL-13 receptor antagonist. , 1995, Journal of immunology.

[21]  T. Testerman,et al.  Cytokine induction by the immunomodulators imiquimod and S‐27609 , 1995, Journal of leukocyte biology.

[22]  P. Rothman,et al.  IFN-γ represses ε germline transcription and subsequently down-regulates switch recombination to ε , 1994 .

[23]  Richard L. Miller,et al.  Cytokine induction in mice by the immunomodulator imiquimod , 1994, Journal of leukocyte biology.

[24]  U. Reinhold,et al.  Systemic interferon gamma treatment in severe atopic dermatitis. , 1993, Journal of the American Academy of Dermatology.

[25]  M. Boguniewicz,et al.  Recombinant interferon gamma therapy for atopic dermatitis. , 1993, Journal of the American Academy of Dermatology.

[26]  J. Bonnefoy,et al.  CD21 is a ligand for CD23 and regulates IgE production , 1992, Nature.

[27]  M J Reiter,et al.  Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. , 1992, Cancer research.

[28]  C. Figdor,et al.  IFN-alpha and IFN-gamma have different regulatory effects on IL-4-induced membrane expression of Fc epsilon RIIb and release of soluble Fc epsilon RIIb by human monocytes. , 1990, Journal of immunology.

[29]  D. Bernstein,et al.  Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. , 1988, Antiviral research.

[30]  T. Gajewski,et al.  Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. , 1988, Journal of immunology.

[31]  M. Chen,et al.  Efficacy of S26308 against guinea pig cytomegalovirus infection , 1988, Antimicrobial Agents and Chemotherapy.

[32]  J. Bonnefoy,et al.  Structure and functions of CD23. , 1997, International reviews of immunology.

[33]  R. Coffman,et al.  Mechanism and regulation of immunoglobulin isotype switching. , 1993, Advances in immunology.